Editorial - Technological innovation and health regulation
Vigil Sanit Debate, Rio de Janeiro, 2026, v.14: e02658| Published on: 2026-05-04
DOI:
https://doi.org/10.22239/2317-269x.02658Keywords:
Technological Innovation, Health RegulationAbstract
This section of the Visa in Debate magazine presents evidence produced by strategic studies, the result of cooperation between the Oswaldo Cruz Foundation Brasília (Fiocruz Brasília) and the National Health Surveillance Agency (Anvisa), with the purpose of supporting the regulatory decision-making process.
Downloads
References
1. Organisation for Economic Co-operation and Development – OECD. Manual de Oslo: proposta de diretrizes para coleta e interpretação de dados sobre inovação tecnológica. 3a ed. Paris: Organisation for Economic Co-operation and Development; 2004.
2. Sounderajah V, Patel V, Varatharajan L, Harling L, Normahani P, Symons J et al. Are disruptive innovations recognised in the healthcare literature?A systematic review. BMJ Innov. 2021;7(1):208-16.https://doi.org/10.1136/bmjinnov-2020-000424
3. Agência Nacional de Vigilância Sanitária - Anvisa. Portaria Nº 1.484, de 15 de dezembro de 2025. Aprova a agenda regulatória da Anvisa para o biênio 2026-2027.Brasília: Anvisa; 2025[acesso 15 fev 2026]. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/regulamentacao/agenda-regulatoria/agenda-2026-2027
4. Darrow JJ, Avorn J, Kesselheim AS. FDA Regulation and Approval of Medical Devices: 1976-2020. JAMA. 2021;326(5):420-32.https://doi.org/10.1001/jama.2021.11171
5. Warraich HJ, Tazbaz T, Califf RM. FDA Perspective on the regulation of artificial intelligence in health care and biomedicine. JAMA. 2025;333(3):241-7.https://doi.org/10.1001/jama.2024.21451
6. Joshi G, Jain A, Araveeti SR, Adhikari S, Garg H, Bhandari M. FDA-approved artificial intelligence and machine learning (ai/ml)-enabled medical devices: an updated landscape. Electronics. 2024;13(3):1-15.https://doi.org/10.3390/electronics13030498
7. Wasiullah P, Yadav P, Yadav S, Yadav P, Yadav R. Pharmaceutical regulatory agencies and organization around the world scope and challenges in drug development. Int J Pharm Res Appl. 2025;10(1):2765-9.https://doi.org/10.35629/4494-100227652769
8. Balakumar P, Mulukuri NVLS, Jagadeesh G. A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation. Pharmacol Ther. 2026;277:108945.https://doi.org/10.1016/j.pharmthera.2025.108945
9. Gomase VS, Sharma R, Dhamane SP. Global analysis of regulatory frameworks and drug safety standards in the drug approval process. Curr Drug Saf. 4 set 2025.https://doi.org/10.2174/0115748863392869250827042742
10. Kuveria H, Patel Z, Raval M, Zaveri M. Overview and lifecycle management of generic pharmaceutical drugs in Mexico, Guatemala and Brazil. Int J Drug Regul Aff. 2024;12(2):67-76. https://doi.org/10.22270/ijdra.v12i2.676
11. Fonseca EMD. Reforming pharmaceutical regulation: a case study of generic drugs in Brazil. Policy Soc. 2014;33(1):65-76.https://doi.org/10.1016/j.polsoc.2014.03.004
12. Ribeiro AA, Acosta A, Pontes MA, Machado Beltran MA, Peixoto RT, Leite SN. Transparency of data on the value chain of medicines in Argentina, Brazil, and Colombia. Front Pharmacol. 2023 Jan 5;13:1-18.https://doi.org/10.3389/fphar.2022.1063300
13. Agência Nacional de Vigilância Sanitária - Anvisa. Resolução RDC Nº 1.014, de 30 de janeiro de 2026. Institui o sandbox regulatório para produtos de cannabis medicinal.Diário Oficial União. 3 fev 2026.
14. Agência Nacional de Vigilância Sanitária - Anvisa. Portaria Nº 124, de 6 de fevereiro de 2026. Institui o comitê de acompanhamento regulatório da inovação em saúde no âmbito da Agência Nacional de Vigilância Sanitária (Anvisa). Diário Oficial União. 10 fev 2026.
15. Gadelha CAG. Complexo econômico-industrial da saúde: a base econômica e material do Sistema Único de Saúde. Cad Saúde Pública. 2022;38:1-17.https://doi.org/10.1590/0102-311X00263321
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Health Surveillance under Debate: Society, Science & Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
COPYRIGHT ALLOWANCE The author (s) hereinafter designated as the ASSIGNOR hereby assign and transfer, free of charge, the ownership of the copyrights related to this ARTICLE to the Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debate, represented by FUNDAÇÃO OSWALDO CRUZ, established at Av. Brasil, nº 4365, Manguinhos, Rio de Janeiro, RJ, Brazil, CEP 21045-900, under the conditions set out below: (a) The terms and conditions set forth in this Agreement shall apply to the following: 1. The ASSIGNOR declares that they s(he) is (are) the author (s) and owner (s) of the copyrighted property of the ARTICLE submitted. 2. The ASSIGNOR declares that the ARTICLE does not infringe the copyrights and / or other property rights of third parties, that the disclosure of images (if any) has been authorized and that they s(he) assume(s) full moral and / or property liability for its content, before third parties. 3. THE ASSIGNOR assigns and transfers all copyrights relating to the ARTICLE to the ASSIGNEE, especially the rights of editing, publication, translation into another language and reproduction by any process or technique. The ASSIGNEE becomes the exclusive owner of the rights related to the ARTICLE, and any reproduction, totally or partially, is prohibited in any other means of publicity, printed or electronic, without prior written authorization from the ASSIGNEE. 4. The assignment is free and, therefore, there will be no remuneration for the use of the ARTICLE by the ASSIGNEE.
